{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T17:10:18Z","timestamp":1784221818037,"version":"3.55.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T00:00:00Z","timestamp":1709683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T00:00:00Z","timestamp":1709683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001700","name":"MEXT","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1007\/s40261-024-01352-4","type":"journal-article","created":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T12:02:08Z","timestamp":1709726528000},"page":"261-269","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Effectiveness of Dose Increase in Upadacitinib from 15 mg to 30 mg for Patients with Moderate-to-Severe Atopic Dermatitis: A Real-World Clinical Practice in Japan"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4183-9596","authenticated-orcid":false,"given":"Teppei","family":"Hagino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Risa","family":"Hamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1095-0355","authenticated-orcid":false,"given":"Hidehisa","family":"Saeki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eita","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4389-2312","authenticated-orcid":false,"given":"Naoko","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,6]]},"reference":[{"key":"1352_CR1","doi-asserted-by":"crossref","unstructured":"Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014;70(2):338\u201351","DOI":"10.1016\/j.jaad.2013.10.010"},{"issue":"3","key":"1352_CR2","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/j.1525-1470.2005.22303.x","volume":"22","author":"CL Carroll","year":"2005","unstructured":"Carroll CL, Balkrishnan R, Feldman SR, et al. The burden of atopic dermatitis: impact on the patient, family, and society. Pediatr Dermatol. 2005;22(3):192\u20139.","journal-title":"Pediatr Dermatol."},{"issue":"10290","key":"1352_CR3","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1016\/S0140-6736(21)00588-2","volume":"397","author":"E Guttman-Yassky","year":"2021","unstructured":"Guttman-Yassky E, Teixeira HD, Simpson EL, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet. 2021;397(10290):2151\u201368.","journal-title":"Lancet"},{"issue":"3","key":"1352_CR4","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.jaci.2019.11.025","volume":"145","author":"E Guttman-Yassky","year":"2020","unstructured":"Guttman-Yassky E, Tha\u00e7i D, Pangan AL, et al. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2020;145(3):877\u201384.","journal-title":"J Allergy Clin Immunol"},{"issue":"10290","key":"1352_CR5","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1016\/S0140-6736(21)00589-4","volume":"397","author":"K Reich","year":"2021","unstructured":"Reich K, Teixeira HD, de Bruin-Weller M, et al. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2021;397(10290):2169\u201381.","journal-title":"Lancet"},{"issue":"11","key":"1352_CR6","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1111\/1346-8138.16549","volume":"49","author":"T Hagino","year":"2022","unstructured":"Hagino T, Saeki H, Kanda N. The efficacy and safety of upadacitinib treatment for moderate to severe atopic dermatitis in real-world practice in Japan. J Dermatol. 2022;49(11):1158\u201367.","journal-title":"J Dermatol"},{"issue":"1","key":"1352_CR7","doi-asserted-by":"publisher","first-page":"2276043","DOI":"10.1080\/09546634.2023.2276043","volume":"34","author":"T Hagino","year":"2023","unstructured":"Hagino T, Yoshida M, Hamada R, et al. Effectiveness of switching from baricitinib 4 mg to upadacitinib 30 mg in patients with moderate-to-severe atopic dermatitis: a real-world clinical practice in Japan. J Dermatolog Treat. 2023;34(1):2276043.","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"1352_CR8","doi-asserted-by":"publisher","first-page":"2291317","DOI":"10.1080\/09546634.2023.2291317","volume":"35","author":"T Hagino","year":"2024","unstructured":"Hagino T, Yoshida M, Hamada R, et al. Early itch relief with upadacitinib predicts later skin clearance in atopic dermatitis. J Dermatolog Treat. 2024;35(1):2291317.","journal-title":"J Dermatolog Treat"},{"issue":"6","key":"1352_CR9","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1007\/s40257-023-00798-0","volume":"24","author":"A Chiricozzi","year":"2023","unstructured":"Chiricozzi A, Ortoncelli M, Schena D, et al. Long-term effectiveness and safety of upadacitinib for atopic dermatitis in a real-world setting: an interim analysis through 48 weeks of observation. Am J Clin Dermatol. 2023;24(6):953\u201361.","journal-title":"Am J Clin Dermatol"},{"issue":"9","key":"1352_CR10","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1111\/jdv.19232","volume":"37","author":"JP Thyssen","year":"2023","unstructured":"Thyssen JP, Tha\u00e7i D, Bieber T, et al. Upadacitinib for moderate-to-severe atopic dermatitis: stratified analysis from three randomized phase 3 trials by key baseline characteristics. J Eur Acad Dermatol Venereol. 2023;37(9):1871\u201380.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"1352_CR11","doi-asserted-by":"publisher","first-page":"e352","DOI":"10.1111\/ajd.14139","volume":"64","author":"V Tran","year":"2023","unstructured":"Tran V, Ross G. A real-world Australian experience of upadacitinib for the treatment of severe atopic dermatitis. Australas J Dermatol. 2023;64(4):e352\u20136.","journal-title":"Australas J Dermatol"},{"issue":"6","key":"1352_CR12","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1684\/ejd.2022.4365","volume":"32","author":"K Kosaka","year":"2022","unstructured":"Kosaka K, Uchiyama A, Ishikawa M, et al. Real-world effectiveness and safety of upadacitinib in Japanese patients with atopic dermatitis: a two-centre retrospective study. Eur J Dermatol. 2022;32(6):800\u20132.","journal-title":"Eur J Dermatol"},{"issue":"4","key":"1352_CR13","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.alit.2022.06.009","volume":"71","author":"H Saeki","year":"2022","unstructured":"Saeki H, Ohya Y, Furuta J, et al. Executive summary: Japanese guidelines for atopic dermatitis (ADGL) 2021. Allergol Int. 2022;71(4):448\u201358.","journal-title":"Allergol Int"},{"issue":"10","key":"1352_CR14","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1007\/s13555-023-01000-3","volume":"13","author":"JI Silverberg","year":"2023","unstructured":"Silverberg JI, Hong HC, Calimlim BM, et al. Comparative efficacy of targeted systemic therapies for moderate-to-severe atopic dermatitis without topical corticosteroids: an updated network meta-analysis. Dermatol Ther (Heidelb). 2023;13(10):2247\u201364.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"1","key":"1352_CR15","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13688","volume":"17","author":"MF Mohamed","year":"2024","unstructured":"Mohamed MF, Bhatnagar S, Parmentier JM, et al. Upadacitinib: mechanism of action, clinical, and translational science. Clin Transl Sci. 2024;17(1): e13688.","journal-title":"Clin Transl Sci"},{"issue":"1","key":"1352_CR16","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1186\/s13075-019-1964-1","volume":"21","author":"IB McInnes","year":"2019","unstructured":"McInnes IB, Byers NL, Higgs RE, et al. Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations. Arthritis Res Ther. 2019;21(1):183.","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"1352_CR17","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1136\/annrheumdis-2020-219012","volume":"80","author":"PG Traves","year":"2021","unstructured":"Traves PG, Murray B, Campigotto F, et al. JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib. Ann Rheum Dis. 2021;80(7):865\u201375.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"1352_CR18","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1002\/jcph.1513","volume":"60","author":"MF Mohamed","year":"2020","unstructured":"Mohamed MF, Beck D, Camp HS, et al. Preferential inhibition of JAK1 relative to JAK3 by upadacitinib: exposure-response analyses of ex vivo data from 2 phase 1 clinical trials and comparison to tofacitinib. J Clin Pharmacol. 2020;60(2):188\u201397.","journal-title":"J Clin Pharmacol"},{"issue":"10","key":"1352_CR19","doi-asserted-by":"publisher","first-page":"3139","DOI":"10.1111\/bcp.15803","volume":"89","author":"M Ismail","year":"2023","unstructured":"Ismail M, Doelger E, Eckert D, et al. Population pharmacokinetic and exposure-response modelling to inform upadacitinib dose selection in adolescent and adult patients with atopic dermatitis. Br J Clin Pharmacol. 2023;89(10):3139\u201351.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"1352_CR20","doi-asserted-by":"publisher","first-page":"2212095","DOI":"10.1080\/09546634.2023.2212095","volume":"34","author":"T Hagino","year":"2023","unstructured":"Hagino T, Saeki H, Fujimoto E, et al. The differential effects of upadacitinib treatment on skin rashes of four anatomical sites in patients with atopic dermatitis. J Dermatolog Treat. 2023;34(1):2212095.","journal-title":"J Dermatolog Treat"},{"key":"1352_CR21","doi-asserted-by":"publisher","first-page":"3201","DOI":"10.2147\/CCID.S439053","volume":"16","author":"T Hagino","year":"2023","unstructured":"Hagino T, Hamada R, Yoshida M, et al. Effectiveness and safety of upadacitinib in combination with topical corticosteroids in adolescent patients with moderate-to-severe atopic dermatitis. Clin Cosmet Investig Dermatol. 2023;16:3201\u201312.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"5","key":"1352_CR22","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1111\/jdv.18849","volume":"37","author":"I Vittrup","year":"2023","unstructured":"Vittrup I, Krogh NS, Larsen HHP, et al. A nationwide 104 weeks real-world study of dupilumab in adults with atopic dermatitis: ineffectiveness in head-and-neck dermatitis. J Eur Acad Dermatol Venereol. 2023;37(5):1046\u201355.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1352_CR23","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.jaad.2008.07.058","volume":"60","author":"K Darabi","year":"2009","unstructured":"Darabi K, Hostetler SG, Bechtel MA, et al. The role of Malassezia in atopic dermatitis affecting the head and neck of adults. J Am Acad Dermatol. 2009;60(1):125\u201336.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1352_CR24","doi-asserted-by":"publisher","first-page":"e300","DOI":"10.1111\/jdv.18743","volume":"37","author":"H Uchida","year":"2023","unstructured":"Uchida H, Kamata M, Egawa S, et al. Newly developed erythema and red papules in the face and neck with detection of demodex during dupilumab treatment for atopic dermatitis improved by discontinuation of dupilumab, switching to upadacitinib or treatment with oral ivermectin: a report of two cases. J Eur Acad Dermatol Venereol. 2023;37(3):e300\u20132.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"1352_CR25","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1111\/all.15569","volume":"78","author":"H Yin","year":"2023","unstructured":"Yin H, Qiu Z, Zhu R, et al. Dysregulated lipidome of sebum in patients with atopic dermatitis. Allergy. 2023;78(6):1524\u201337.","journal-title":"Allergy"},{"issue":"7","key":"1352_CR26","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1111\/1346-8138.16763","volume":"50","author":"T Hagino","year":"2023","unstructured":"Hagino T, Saeki H, Fujimoto E, et al. Efficacy and safety of baricitinib treatment for moderate to severe atopic dermatitis in real-world practice in Japan. J Dermatol. 2023;50(7):869\u201379.","journal-title":"J Dermatol"},{"issue":"5","key":"1352_CR27","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20190472","volume":"217","author":"Z Yang","year":"2020","unstructured":"Yang Z, Wu CM, Targ S, et al. IL-21 is a broad negative regulator of IgE class switch recombination in mouse and human B cells. J Exp Med. 2020;217(5): e20190472.","journal-title":"J Exp Med"},{"key":"1352_CR28","unstructured":"U.S. Food and Drug Administration. FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions: 1 Sep 2021. Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-requires-warnings-about-increased-riskserious-heart-related-events-cancer-blood-clots-and-death. Accessed 4 Mar 2024."}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-024-01352-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-024-01352-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-024-01352-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,30]],"date-time":"2024-03-30T02:19:23Z","timestamp":1711765163000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-024-01352-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,6]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["1352"],"URL":"https:\/\/doi.org\/10.1007\/s40261-024-01352-4","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,6]]},"assertion":[{"value":"25 February 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No funding was received to conduct this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Teppei Hagino, Hidehisa Saeki, and Naoko Kanda received lecture fees from AbbVie GK. Risa Hamada, Mai Yoshida, and Eita Fujimoto have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki, and approved by the Ethics Committee of Nippon Medical School Chiba Hokusoh Hospital (protocol code H-2022-945; approval date 10 February 2022).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written consent was provided by the patients.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The datasets used and\/or analyzed during the current study are available from the corresponding author upon reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"TH conceptualized the study, and mainly organized the manuscript. MY and RH performed the statistical analyses. NK supervised the study. HS and EF revised the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}